SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ProMetic Life Sciences
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cush who wrote (159)12/19/2017 1:35:39 PM
From: axial1 Recommendation

Recommended By
The Ox

  Read Replies (1) of 250
 
Hi Cush — Sometime soon, we should discuss off-label uses for PBI-4050 and Ryplazim. To avoid the perception of pumping I've avoided the subject: still speculative. However readers should be aware of the enormous potential.

In the meantime, it appears that Prometic is a testing a combined attack on fibrosis, particularly in the lungs.

Does this morning's PR about orphan status for PG to treat IPF mean that PLI is now looking at a two prong attack on IPF using both PG AND 4050 to treat IPF? This sounds new to me. Has this new approach been made public before?
____________________________________________

Fred responded as follows:

Hi .......,

This is indeed new info for the public. We have been waiting for a while for the orphan drug designation and finally received it.

If demonstrated efficacious in IPF, plasminogen would be used in IPF patients that are undergoing Acute exacerbations…just like patients with Acute Lung Injury…
In other words, plasminogen would be used in the Hospitals / ICUs whilst PBI-4050 would be chronic / once daily therapy.

When we say that “we are the company that can effectively address the entire healing process in a ground-breaking way using both small molecule drugs and plasma protein therapies…” this is not a joke, we really do have a deep understanding of the healing process…

Cheers,

Fred
Frederic Dumais
Directeur principal, Communications et relations avec les investisseurs, Senior Director, Communications and Investor Relations
440 Boul. Armand-Frappier
Laval, Quebec H7V 4B4
+1 450 781 0115
f.dumais@prometic.com
____________________________________________

Jim
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News